September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Investigation of the role of cysteinyl leukotrienes in ocular developmental angiogenesis.
Author Affiliations & Notes
  • Alison L Reynolds
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, Dublin, Ireland
  • Jessica Garcia Fernandez
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, Dublin, Ireland
  • Janina Osman
    Lund University, Lund, Sweden
  • Pilar Ventosa
    Gadea Pharmaceutical Group, Valladolid, Spain
  • Yolanda Fernandez
    Gadea Pharmaceutical Group, Valladolid, Spain
  • Anita Sjölander
    Lund University, Lund, Sweden
  • Breandan N Kennedy
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, Dublin, Ireland
  • Footnotes
    Commercial Relationships   Alison Reynolds, PCT/EP2015/050710 (P), WO2012095836A1 (P), WO 2014/012889 A1 (P); Jessica Garcia Fernandez, None; Janina Osman, None; Pilar Ventosa, None; Yolanda Fernandez, None; Anita Sjölander, None; Breandan Kennedy, PCT/EP2015/050710 (P), WO2012095836A1 (P), WO 2014/012889 A1 (P)
  • Footnotes
    Support  HRA-POR-2013-390
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5026. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alison L Reynolds, Jessica Garcia Fernandez, Janina Osman, Pilar Ventosa, Yolanda Fernandez, Anita Sjölander, Breandan N Kennedy; Investigation of the role of cysteinyl leukotrienes in ocular developmental angiogenesis.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5026.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Previously, we identified quininib (2-[(E)-2-(quinolin-2-yl)vinyl] phenol) and a related series of cysteinyl leukotriene (cysLT) receptor antagonists which inhibit hyaloid vessel development in zebrafish eyes. Here, we more comprehensively characterise the expression and function of specific cysLT signalling components in ocular developmental angiogenesis.

Methods : More than 40 analogues of the cysLT receptor antagonist, quininib, were synthesised. Anti-angiogenic activity of each compound was ranked based on inhibition of hyaloid vessel formation in Tg[fli1:EGFP] zebrafish eyes. cysLT receptor antagonism was quantified using reporter cell bioassays. Inhibition of mammalian developmental retinal angiogenesis was determined by sub-cutaneous delivery of quininib in postnatal day (P)1 pups with quantification of retinal vasculature at P4 and P8. The requirement of cysLT receptors for retinal angiogenesis is being assessed in cysLT1R and cysLT2R knockout mice. An assessment of the spatial and temporal expression of cysLT receptors in developing mouse eyes will be performed by Western blot and immunohistochemistry.

Results : Nine quininib analogues inhibit hyaloid vasculature development equal to or greater than the parent compound. Seven quininib analogues significantly inhibited leukotriene D4 activation of CysLT1R and enhanced inhibition of CysLT2R activation compared to quininib. In a pilot study, 50 mg/kg quininib (n = 4) inhibited developmental retinal angiogenesis in mice by 20% compared to vehicle injected controls (n = 3; p-val =0.024). Preliminary results from Cysltr1 and Cysltr2 knockout mice (N = 3/group) suggests Cysltr2 knockouts show 20% delay in retinal vascular formation.

Conclusions : Cysteinyl leukotriene signalling regulates ocular developmental angiogenesis. The cysteinyl leukotriene pathway is a therapeutic target for inhibiting aberrant pathological angiogenesis which occurs in age-related macular degeneration and diabetic retinopathy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×